• Product NameAtractylenolide III
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityAtractylenolide III may have therapeutic potential in treating homocysteine-mediated cognitive impairment and neuronal injury. Atractylenolide III is a potential candidate for treatment of human lung carcinoma by inducing the release of cytochrome c, upregulating the expression of bax and translocating apoptosis-inducing factor.
• Target NameApoptosis inducer inhibitor
• CAS No. 73030-71-4
• Calculated MW 248.322
• Formulation C15H20O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Others
  SMILES:CC1=C2C[C@H]3C(=C)CCC[C@@]3(C[C@@]2(OC1=O)O)C
  Pathways:Apoptosis
  Receptor:Apoptosis inducer
  Boling pt:
  Melting pt:
  Solubility:Soluble in Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetonel
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Zhao H,et al. Neuroprotection and mechanisms of atractylenolide III in preventing learning and memory impairment induced by chronic high-dose homocysteine administration in rats. Neuroscience. 2015 Apr 2;290:485-91.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting